FAPIC: Fast Assay for Pathogen Identification and Characterization

Sponsor
Hasselt University (Other)
Overall Status
Completed
CT.gov ID
NCT03841162
Collaborator
Jessa Hospital (Other), University of Zagreb (Other), Molzym (Other), AIT Austrian Institute of Technology GmbH (Other), BEE Robotics (Other), University of Warwick (Other), Claude Bernard University (Other), Axo Science (Other)
1,957
1
14.1
138.5

Study Details

Study Description

Brief Summary

Sepsis is a life-threatening disease caused by a dysregulated host response to infection. This can lead to organ-dysfunction and septic shock, which is a subset of sepsis where underlying abnormalities increase mortality remarkably. Blood cultures are the gold standard for identifying pathogens in the bloodstream (bacteremia). It is based on cultivation techniques which, theoretically, can detect a single pathogenic cell from a patient sample. However, blood cultures have serious limitations, such as long time to result (3-7 days). This leads to the fact that only a small fraction of the patients obtain a correct diagnosis and in further consequence get the optimal antimicrobial treatment. Patients with sepsis should get antimicrobial treatment within the hour. Thus, physicians start treatment empirically, with broad-spectrum antibiotics. This puts a selective pressure on pathogens and has led to an increased amount of antibiotic resistance. Faster diagnostics are necessary to ensure an immediate and targeted treatment. In the EU-funded FAPIC project, two diagnostic systems that can be used with direct sample material from patients will be developed, avoiding the time-consuming cultivation of pathogens.

In this study, the evaluation of the rapid diagnostics will be performed in patients with sepsis, suspected of bacteremia. To this aim, the performance of the diagnostic systems will be evaluated using blood samples that are collected in parallel with blood cultures. In addition, clinical data of the patients will be collected. In routine care, two blood culture sets (2x2 bottles) per patient are collected. One extra blood samples (EDTA, 9 ml) will be sampled with each blood culture set, totaling 2 samples per patient. In this study, patients presenting at the Emergency Department (ED), and the department of infectious diseases/nephrology will be included. The results will be used to estimate the performance, sensitivity, and specificity of the diagnostic systems compared to blood culture. Furthermore, in order to determine the severity of sepsis and to describe the patient population, clinically relevant parameters and laboratory parameters (ferritin, HLA-DR, serum lactate, SOFA score) will be assessed to determine its association with severity of disease and patient mortality. Evaluation will be done exclusively in the lab, and will not be used directly for the diagnosis or management of patients. Standard care will still be provided.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    This study is a follow-up study of the first prospective study performed in 2017 in the same hospital. The ClinicalTrials.gov ID number of the previous study was NCT03025802.

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    1957 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Fast Assay for Pathogen Identification and Characterization - Prospective Observational Study
    Actual Study Start Date :
    Feb 12, 2019
    Actual Primary Completion Date :
    Apr 17, 2020
    Actual Study Completion Date :
    Apr 17, 2020

    Arms and Interventions

    Arm Intervention/Treatment
    Patients with suspected sepsis

    Patients for whom blood cultures are drawn at the Emergency Department or the department of Infectious Diseases/Nephrology

    Outcome Measures

    Primary Outcome Measures

    1. Confirmed bacteremia based on positive blood cultures (SOFA score) [7 days]

      Differences in SOFA score between patients with positive blood cultures and patients with negative blood cultures. SOFA: Sequential Organ Failure Assessment; Range 0-4 (better to worse).

    2. Confirmed bacteremia based on positive blood cultures (Serum Lactate) [7 days]

      Differences in Serum Lactate levels between patients with positive blood cultures and patients with negative blood cultures

    3. Confirmed bacteremia based on positive blood cultures (Ferritin) [7 days]

      Differences in Ferritin levels between patients with positive blood cultures and patients with negative blood cultures

    4. Test performance [1 year]

      Performance characteristics (Clinical sensitivity, specificity and accuracy) of a new rapid diagnostic systems

    Secondary Outcome Measures

    1. Length of Stay (SOFA score) [1 year]

      Differences in length of stay between patients with high and with low SOFA score SOFA: Sequential Organ Failure Assessment; Range 0-4 (better to worse).

    2. Length of Stay (Serum Lactate) [1 year]

      Differences in length of stay between patients with high and with low Serum Lactate levels

    3. Length of Stay (Ferritin) [1 year]

      Differences in length of stay between patients with high and with low Ferritin levels

    4. 30-day Mortality (Sofa score) [30 days]

      Differences in 30-day mortality between patients with high and with low SOFA score SOFA: Sequential Organ Failure Assessment; Range 0-4 (better to worse).

    5. 30-day Mortality (Serum Lactate) [30 days]

      Differences 30-day mortality between patients with high and with low Serum Lactate levels

    6. 30-day Mortality (Ferritin) [30 days]

      Differences 30-day mortality between patients with high and with low Ferritin levels

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Patients for whom blood cultures are drawn

    • Age ≥ 18

    Exclusion Criteria:
    • Age < 18

    • Patients who are not hospitalized and sent home after ED admission

    • Patients from the haematology department

    • Duplicate blood cultures from the same bacteraemia episode (blood cultures drawn <7 days after first blood culture)

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Jessa Hospital Hasselt Limburg Belgium 3500

    Sponsors and Collaborators

    • Hasselt University
    • Jessa Hospital
    • University of Zagreb
    • Molzym
    • AIT Austrian Institute of Technology GmbH
    • BEE Robotics
    • University of Warwick
    • Claude Bernard University
    • Axo Science

    Investigators

    • Principal Investigator: Inge C Gyssens, MD, PhD, Radboud University Medical Center

    Study Documents (Full-Text)

    None provided.

    More Information

    Additional Information:

    Publications

    Responsible Party:
    prof. dr. Inge Gyssens, Principal Investigator, Radboud University Medical Center
    ClinicalTrials.gov Identifier:
    NCT03841162
    Other Study ID Numbers:
    • 18.106/infect18.03
    First Posted:
    Feb 15, 2019
    Last Update Posted:
    Apr 29, 2020
    Last Verified:
    Apr 1, 2020
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by prof. dr. Inge Gyssens, Principal Investigator, Radboud University Medical Center
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Apr 29, 2020